Adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for pancreatic adenocarcinoma

被引：50

作者：

Murakami, Yoshiaki ^{[1
]}

Uemura, Kenichiro ^{[1
]}

Sudo, Takeshi ^{[1
]}

Hayashidani, Yasuo ^{[1
]}

Hashimoto, Yasushi ^{[1
]}

Nakagawa, Naoya ^{[1
]}

Ohge, Hiroki ^{[1
]}

Sueda, Taijiro ^{[1
]}

机构：

[1] Hiroshima Univ, Dept Surg, Div Clin Med Sci, Grad Sch Biomed Sci, Hiroshima, Japan

来源：

AMERICAN JOURNAL OF SURGERY | 2008年 / 195卷 / 06期

关键词：

gemcitabine; pancreatic carcinoma; postsurgical adjuvant chemotherapy; S-1; two-year survival rate;

D O I：

10.1016/j.amjsurg.2007.04.018

中图分类号：

R61 [外科手术学];

学科分类号：

摘要：

BACKGROUND: The aim of this study was to determine the effectiveness of adjuvant gemcitabine plus S-1 chemotherapy for patients with pancreatic carcinoma. METHODS: Patients admitted for curative surgery for pancreatic adenocarcinoma. received adjuvant chemotherapy with 10 cycles of gemcitabine plus S-I every 2 weeks. Each chemotherapy cycle consisted of intravenous gemcitabine, 700 mg/m(2), on day 1 and orally administered S-1, 50 mg/m(2), for 7 consecutive days, after which there was a 1-week pause of chemotherapy. RESULTS: Twenty-seven patients were entered into this study. According to the TNM system, 4 (15%), 2 (7%), 6 (22%), and 15 (56%) patients were diagnosed with stage IA, IB, IIA, and IIB disease, respectively. Overall and disease-free survival rates were 86% and 60% at 1 year, 66% and 45% at 2 years, and 33% and 45% at 3 years, respectively. Toxicity during chemotherapy was mild. CONCLUSIONS: Adjuvant gemcitabine plus S-1 chemotherapy appears to be a promising treatment for patients after surgical resection of pancreatic adenocarcinoma. (C) 2008 Elsevier Inc. All rights reserved.

引用

页码：757 / 762

页数：6

共 43 条

[1]

[Anonymous], 1987, Cancer, V59, P2006

[2] ADJUVANT COMBINATION CHEMOTHERAPY (AMF) FOLLOWING RADICAL RESECTION OF CARCINOMA OF THE PANCREAS AND PAPILLA OF VATER - RESULTS OF A CONTROLLED, PROSPECTIVE, RANDOMIZED MULTICENTER STUDY [J].

BAKKEVOLD, KE ;

ARNESJO, B ;

DAHL, O ;

KAMBESTAD, B .

EUROPEAN JOURNAL OF CANCER, 1993, 29A (05) :698-703

[3] Increased preoperative platelet count is associated with decreased survival after resection for adenocarcinorna of the pancreas [J].

Brown, KM ;

Domin, C ;

Aranha, GV ;

Yong, S ;

Shoup, M .

AMERICAN JOURNAL OF SURGERY, 2005, 189 (03) :278-282

[4] Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial [J].

Burris, HA ;

Moore, MJ ;

Andersen, J ;

Green, MR ;

Rothenberg, ML ;

Madiano, MR ;

Cripps, MC ;

Portenoy, RK ;

Storniolo, AM ;

Tarassoff, P ;

Nelson, R ;

Dorr, FA ;

Stephens, CD ;

VanHoff, DD .

JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (06) :2403-2413

[5] A prospective randomized trial comparing standard pancreatoduodenectomy with pancreatoduodenectomy with extended lymphadenectomy in resectable pancreatic head adenocarcinoma [J].

Farnell, MB ;

Pearson, RK ;

Sarr, MG ;

DiMagno, EP ;

Burgart, LJ ;

Dahl, TR ;

Foster, N ;

Sargent, DJ .

SURGERY, 2005, 138 (04) :618-628

[6] PATTERNS OF FAILURE IN GROSSLY RESECTED PANCREATIC DUCTAL ADENOCARCINOMA TREATED WITH ADJUVANT IRRADIATION +/- 5-FLUOROURACIL [J].

FOO, ML ;

GUNDERSON, LL ;

NAGORNEY, DM ;

MCLLRATH, DC ;

VANHEERDEN, JA ;

ROBINOW, JS ;

KVOLS, LK ;

GARTON, GR ;

MARTENSON, JA ;

CHA, SS .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1993, 26 (03) :483-489

[7] Prognostic factors in the operative treatment of ductal pancreatic carcinoma [J].

Gebhardt, C ;

Meyer, W ;

Reichel, M ;

Wünsch, PH .

LANGENBECKS ARCHIVES OF SURGERY, 2000, 385 (01) :14-20

[8]

International Union against Cancer, 2002, TNM CLASS MAL TUM

[9] Cancer statistics, 2006 [J].

Jemal, A ;

Siegel, R ;

Ward, E ;

Murray, T ;

Xu, JQ ;

Smigal, C ;

Thun, MJ .

CA-A CANCER JOURNAL FOR CLINICIANS, 2006, 56 (02) :106-130

[10]

KALSER MH, 1985, ARCH SURG-CHICAGO, V120, P899

← 1 2 3 4 5 →